W&P Pharmaceuticals (CEO Hong Chang-hee) announced that it will participate in ‘BIO KOREA 5 (Bio Korea 10)’, which will be held at COEX in Seoul for three days from Wednesday, May 12th to Friday, May 3th.
W&P Pharmaceutical is a global CRO (Contract Research Organization) headquartered in the UK. Support services. It has been providing services in the three major regions of the international pharmaceutical market, including the EU, the US, and Asia, and plans to expand its presence in Korea and begin its journey as a global CRO by collaborating with local CROs overseas.
Accordingly, W&P Pharmaceutical announced that it can provide customized services for all processes from the initial stage of new drug development to product shipment for global biotechnology and pharmaceutical companies at global sites in approximately 30 countries, including services provided through partners. .
W&P Pharmaceuticals provides the full cycle of services required by bio companies, including non-clinical, efficacy evaluation, preliminary toxicity testing, approved GLP toxicity studies, clinical trials, licensing, and data science through domestic and overseas affiliated CRO. In particular, we aim to conduct systematic and efficient clinical trials in the knowledge management system sector. W&P Pharmaceutical uses eClint®, a virtual data room-in-house clinical trial management solution based on CDISC international clinical data standards, for clinical trial plans and data, shortening the clinical trial period and improving the quality of results by standardizing and automating the clinical research process. Improvement can also be expected.
A strong team of clinical pharmacologists is also considered another strength. Officials explain that, as principal investigators, they safely supervise the research based on their expertise. Based on these advantages, more than 300 studies have been conducted in clinical and non-clinical studies for pharmaceutical, biotechnology and device companies.
Last February, W&P Pharmaceuticals signed an exclusive contract with Leon Research, a global clinical CRO organization, for clinical evaluation of domestic new drug developers. We plan to expand the scope of related business through cooperation with Spain, the world’s third largest clinical trial country. CEO Hong Chang-hee, who was selected as the representative of the Korean branch, graduated from Sungkyunkwan University College of Pharmacy and has experience in new drug development and clinical expertise through working at domestic and overseas bio ventures and CRO. The plan is to focus on securing the Korean market by reflecting the increased status of the Korean market in the global field and building local core personnel.
A W&P Pharmaceutical official said, “We would like to have the opportunity to cooperate with Korean biopharma companies as part of Bio Korea 2023. He explained the background to his participation in the exhibition, saying, “Through the exhibition, we plan to discuss project budgets with specific Korean companies.”
In addition, “Korea’s pharmaceutical industry is growing significantly due to recent innovations in the Korean new drug market, development of supporting industries, and promotion of national policies related to the medical industry. Accordingly, many bio companies and pharmaceutical companies are actively pursuing medical innovation and entering the global market in earnest, and Korea is recognized as a very important region for conducting clinical trials, showing steadily improved competitiveness in the international environment.” As a global-level CRO, our company aims to respond to the unmet demand for domestic clinical trials and systematically manage clinical trials through multi-country clinical trials of domestic and foreign pharmaceutical companies. “We will strive to make W&P Pharmaceuticals known and utilized by domestic new drug developers and biotech companies,” he said.
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.